Guidance

Meningococcal disease and ciprofloxacin: PGD template

Patient group direction (PGD) template to supply or administer ciprofloxacin for meningococcal disease clusters in educational or residential settings.

Applies to England

Documents

Prophylaxis ciprofloxacin for meningococcal disease: PGD template

Request an accessible format.
If you use assistive technology (such as a screen reader) and need a version of this document in a more accessible format, please email [email protected]. Please tell us what format you need. It will help us if you say what assistive technology you use.

Details

This PGD supports the supply or administration of ciprofloxacin to adults and children for the management of clusters of meningococcal disease, when 2 or more cases are reported in educational or residential settings. PGD version 04.00 is valid from 20 October 2022 to 19 October 2025

It can be used when a decision has been made by an experienced member of the UK Health Security Agency Health Protection Team or by the Incident Control Team to offer chemoprophylaxis, for example, to:

  • children and staff of the same preschool group
  • children of the same school year
  • children or students who share a common social activity or a group of friends

The PGD template requires further authorisation by a clinical governance or patient safety lead who has designated responsibility for signing PGDs. It is not legal or valid without this local, formal authorisation.

The authorising commissioning body and providers are responsible for the adoption and governance of use of this PGD. Provider organisations and health professionals should check they are using the current version and only work to a legally authorised PGD from their commissioning body.

Updates to this page

Published 17 February 2017
Last updated 24 October 2022 + show all updates
  1. Added version 04.00 see page 2 for changes.

  2. Added new version of PGD template.

  3. Updated 'Meningococcal disease: PGD template for the supply or administration of ciprofloxacin'.

  4. First published.

Sign up for emails or print this page